Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-β-lactamase gene variants blaVIM-2 and blAVIM-4

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 6, 2003, Pages 1409-1414

  Pournaras, S ^a   Maniati, M ^a   Petinaki, E ^a   Tzouvelekis, L S ^b   Tsakris, A ^c   Legakis, N J ^b   Maniatis, A N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carbapenemases; Greece; Outbreak; Polyclonal

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DNA; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; TOBRAMYCIN;

AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHROMOSOME DELETION; CONTROLLED STUDY; DNA FINGERPRINTING; EPIDEMIC; GENE CASSETTE; GENETIC VARIABILITY; GENOTYPE; GREECE; HOSPITAL; INTEGRON; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLONE CELLS; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VARIATION (GENETICS);

EID: 0038647800     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg239     Document Type: Article

References (10)

1. Livermore, D. M. & Woodford, N. (2000). Carbapenemases: a problem in waiting? Current Opinions in Microbiology 3, 489-95.
2. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrobial Agents and Chemotherapy 43, 1584-90.
3. Poirel, L., Naas, T., Nicolas, D., Collet, L., Bellais, S., Cavallo, J.-D. et al. (2000). Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrobial Agents and Chemotherapy 44, 891-7.
4. Tsakris, A., Pournaras, S., Woodford, N., Palepou, M.-F. I., Babini, G. S., Douboyas, J. et al. (2000). Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. Journal of Clinical Microbiology 38, 1290-2.
5. Mavroidi, A., Tsakris, A., Tzelepi, E., Pournaras, S., Loukova, V. & Tzouvelekis, L. S. (2000). Carbapenem-hydrolysing VIM-2 metallo-β-lactamase in Pseudomonas aeruginosa from Greece. Journal of Antimicrobial Chemotherapy 46, 1041-3.
6. Yan, J.-J., Hsueh, P.-R., Ko, W.-C., Luh, K.-T., Tsai, S.-H., Wu, H.-M. et al. (2001). Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrobial Agents and Chemotherapy 45, 2224-8.
7. VIM-4), in a clinical strain of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 46, 4026-8.
8. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. Journal of Clinical Microbiology 34, 2909-13.
9. VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrobial Agents and Chemotherapy 45, 546-52.
10. Cornaglia, G., Mazzariol, A., Lauretti, L., Rossolini, G. M. & Fontana, R. (2000). Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clinical Infectious Diseases 31, 1119-25.